Drug intelligence / Profile preview

jolkinolide b

Development stage: Preclinical
Modality: Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Administration: Unknown (preclinical Studies Use Cell Culture And Animal Models)

Overview

**Jolkinolide B** is a natural ent-abietane-type diterpenoid lactone isolated primarily from Euphorbia fischeriana and other Euphorbia species[1][2][3][4][6][8]. It exhibits broad pharmacological activity, including anticancer, anti-inflammatory, anti-tuberculosis, and antiviral effects. Mechanistically, Jolkinolide B induces apoptosis in various cancer cells (including gastric cancer, lung cancer, breast cancer, hepatocellular carcinoma, lymphoma, and leukemia)[1][4][6][8]; triggers cell cycle arrest via the ATR-CHK1-CDC25A-Cdk2 pathway[4]; inactivates the β-catenin signaling pathway and downregulates migration/invasion markers in hepatocellular carcinoma[6]; suppresses JAK2/STAT3 signaling in rheumatoid arthritis, leading to decreased inflammation and bone destruction[3]. It also downregulates Akt, STAT3, and mTOR protein levels in endothelial cells[8].

Other names: 37905-08-1(1S,3R,8R,10R,11R,12R,17R)-5,12,16,16-tetramethyl-2,7,9-trioxahexacyclo[9.8.0.01,3.04,8.08,10.012,17]nonadec-4-en-6-oneBisoxireno(1,10a:3,4)phenanthro(3,2-b)furan-9(7aH)-one

Targets

STAT3 (Signal Transducer and Activator of Transcription 3)JAK2 (Janus kinase 2)CTNNB1 (Beta-catenin)CDK2 (Cyclin-dependent kinase 2)mTOR (Mammalian target of rapamycin kinase)AKT (RAC-alpha serine/threonine-protein kinase)MSI2 (Musashi RNA-binding protein 2)CDC25A (Cell division cycle 25A phosphatase)

Beyond the preview

Go deeper on jolkinolide b.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on jolkinolide b.

Explore the full profile